Menu
Currency
GWAS Study

Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer.

Ferreiro-Iglesias A, McKay JD, Brenner N et al.

34642315 PubMed ID
GWAS Study Type
6334 Participants
21 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

FA
Ferreiro-Iglesias A
MJ
McKay JD
BN
Brenner N
VS
Virani S
LC
Lesseur C
GV
Gaborieau V
NA
Ness AR
HR
Hung RJ
LG
Liu G
DB
Diergaarde B
OA
Olshan AF
HN
Hayes N
WM
Weissler MC
SL
Schroeder L
BN
Bender N
PM
Pawlita M
TS
Thomas S
PM
Pring M
DT
Dudding T
KB
Kanterewicz B
FR
Ferris R
TS
Thomas S
BY
Brhane Y
DV
Díez-Obrero V
MM
Milojevic M
SK
Smith-Byrne K
MD
Mariosa D
JM
Johansson MJ
HR
Herrero R
BS
Boccia S
CG
Cadoni G
LM
Lacko M
HI
Holcátová I
AW
Ahrens W
LP
Lagiou P
LA
Lagiou A
PJ
Polesel J
SL
Simonato L
MF
Merletti F
HC
Healy CM
HB
Hansen BT
NM
Nygård M
CD
Conway DI
WS
Wright S
MT
Macfarlane TV
RM
Robinson M
AL
Alemany L
AA
Agudo A
ZA
Znaor A
AC
Amos CI
WT
Waterboer T
BP
Brennan P
Chapter II

Abstract

Summary of the research findings

Although several oropharyngeal cancer (OPC) susceptibility loci have been identified, most previous studies lacked detailed information on human papillomavirus (HPV) status. We conduct a genome-wide analysis by HPV16 serology status in 4,002 oral cancer cases (OPC and oral cavity cancer (OCC)) and 5,256 controls. We detect four susceptibility loci pointing to a distinct genetic predisposition by HPV status. Our most notable finding in the HLA region, that is now confirmed to be specific of HPV(+)OPC risk, reveal two independent loci with strong protective effects, one refining the previously reported HLA class II haplotype association. Antibody levels against HPV16 viral proteins strongly implicate the protective HLA variants as major determinants of humoral response against L1 capsid protein or E6 oncoprotein suggesting a natural immune response against HPV(+)OPC promoted by HLA variants. This indicates that therapeutic vaccines that target E6 and attenuate viral response after established HPV infections might protect against HPV(+)OPC.

1,078 European ancestry cases, 5,256 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

6334
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Norway, Russian Federation, Romania, Republic of Ireland, Spain, Greece, Canada, Czech Republic, Netherlands, Sweden, U.S., Poland, Italy, U.K., Slovakia, France, Germany, Croatia
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.